What Is Gemfibrozil?

Gemfibrozil mainly reduces extremely low-density lipoprotein cholesterol (VLDL-ch) containing the highest total cholesterol (TC), inhibits its functioning of endogenous triglycerides (TG), and reduces TG. However, it reduces the low-density lipoprotein cholesterol (LDL-ch) with the highest cholesterol content, and can only slightly inhibit its functioning. Exogenous cholesterol can be slightly increased, while the high-density lipoprotein cholesterol (HDL-ch) with the highest protein content can be increased Cholesterol content, so there is little reduction in total cholesterol, this effect may be beneficial to inhibit the atherosclerosis process.

Basic Information

Drug Name: Gifibezi
Alias: Nuo Heng, Xyloxepanoic acid, Gefiprozil

Foreign name: Gemfibrozil
Whether prescription drugs: prescription

Gefbezi indication

Mainly suitable for type III, type IV, type and type b hyperlipoproteinemia with increased VLDL-triglyceride.

Gefitizib clinical application

Oral: 1200 mg / day, taken twice in the morning and 30 minutes before dinner. The dose can be increased or decreased according to the situation.

Gefibezi adverse reactions

Lighter, mainly gastrointestinal reactions and fatigue. A few can appear transient aminotransferase elevations, which can be recovered after stopping treatment. This product is a chlorobutyric acid derivative, which may cause myositis, myopathy, and rhabdomyolysis syndrome, leading to an increase in blood creatine phosphokinase. Rhabdomyolysis occurs mainly as myalgia with elevated blood creatine phosphokinase, myoglobinuria, and can cause renal failure, but it is rare. Patients with nephrotic syndrome and other kidney damage leading to decreased albumin or hyperthyroidism have an increased risk of myopathy.

Gefi Betsy notes

1. This product interferes with the diagnosis, which may cause hemoglobin, hematocrit, and white blood cell count. Blood creatine phosphokinase, alkaline phosphatase, aminotransferase, and lactate dehydrogenase may be increased.

2. Periodic inspection should be performed during medication: whole blood and platelet count; liver function test; blood lipid; blood creatine phosphokinase. 3 After 3 months of treatment, the drug should be discontinued if it fails. If the patient develops cholelithiasis, abnormal liver function, suspicious symptoms of myopathy (such as myalgia, tenderness, fatigue, etc.) or a significant increase in blood creatine phosphokinase, the drug should also be stopped.

4. Blood cholesterol and triglyceride may rebound more than the original level after this product is discontinued, so it is advisable to give a low-fat diet and monitor blood lipids to normal.

5. While treating hyperlipidemia, it is necessary to pay attention to and treat various primary diseases that can cause hyperlipidemia, such as hypothyroidism and diabetes. Certain drugs can also cause hyperlipidemia, such as estrogen, thiazide diuretics, and beta blockers. After discontinuation, corresponding antihyperlipidemic treatment is no longer needed.

Gefitibez Contraindications

1. Patients with gallbladder disease and gallstone disease are prohibited. This product may exacerbate the symptoms of patients with gallbladder disease.

2. Patients with liver insufficiency or primary biliary cirrhosis are banned. This product can promote the increase of already high cholesterol levels.

3. Patients with severe renal insufficiency are disabled because taking this product in patients with renal insufficiency may cause rhabdomyolysis and severe hyperkalemia.

4. Patients with reduced serum protein caused by nephrotic syndrome are contraindicated because of increased risk of myopathy.

Gemfibrozil drug interactions

1. This product can significantly enhance the effect of oral anticoagulants. When used with it, pay attention to reduce the dose of oral anticoagulants, and often monitor the prothrombin time to adjust the dose of anticoagulants. Its mechanism of action is uncertain, probably because this product can replace warfarin from its protein binding site, thereby enhancing its effect.

2. When this product is combined with other drugs with a high protein binding rate, they can also be replaced from the protein binding site, resulting in enhanced effects, such as tolbutamide and other sulfonylurea hypoglycemic agents, phenytoin, furfur Sammy et al., Taking the above drugs during the hypolipidemic treatment, should adjust the dose of hypoglycemic agents and other drugs.

3. The combination of chlorobutyric acid derivatives and HMG-CoA reductase inhibitors, such as lovastatin, for the treatment of hyperlipidemia will increase the risk of severe muscle toxicity between the two, which can cause myalgia, rhabdomyolysis, and blood muscle. Myopathies such as acid phosphate kinase elevation should be avoided in combination as much as possible.

4. This product is combined with bile acid resin, such as colestipol, etc., should be taken at least 2 hours before or 2 hours before taking these drugs. Because bile acid binding drugs can be combined with other drugs taken at the same time, and then affect the absorption of other drugs.

5. This product is mainly excreted by the kidney. When combined with immunosuppressive agents such as cyclosporine, it can increase the blood concentration and nephrotoxicity of the latter, which may lead to the deterioration of renal function. It should be reduced or discontinued. Attention should also be paid when this product is used in combination with other nephrotoxic drugs.

Note: The above content is only for introduction, the drug use must be carried out by a regular hospital under the guidance of a doctor.